There are few things better for your physical and mental health than spending time in the Great Outdoors. Unfortunately, even Mother Nature can pose some significant health risks if you’re not careful. Among the most concerning of these pathogens today is the increasing prevalence of tick-borne illnesses, from Rocky Mountain Spotted Fever to Lyme Disease.
Indeed, data derived from global epidemiological trackers, incidence reports, and case studies alike have provided empirical evidence to support what healthcare providers and medical researchers have long suspected: potentially life-threatening tick-borne illnesses are rapidly becoming endemic throughout the world, including the United States (1, 2, 3, 12).
One relatively little-known but increasingly common tick-born pathogen is the parasite Babesia, a protozoan that attacks red blood cells in humans and can lead to a serious, even fatal, malaria-like infection known as Babesiosis, particularly in vulnerable individuals (4). So, how does Babesia affect humans, how is it treated, and what role can integrative medicine play in both prevention and recovery?
What Is Babesia and How Is It Contracted?
Babesia is the second most prevalent blood parasite found in tick-bitten mammals in the United States, with more than 100 species of the microbe having been identified thus far (5). Significantly, a wide variety of mammalian species is susceptible to infection through the bite of an infected tick, including not only humans, but also dogs, sheep, deer, goats, and cattle. Currently, it’s not quite clear whether the parasite can be transmitted to humans through contact with other mammalian hosts (6).
What is clear, however, is that there are three primary ways for a human to become infected with the Babesia parasite. By far the most common of these is direct transmission through the bite of a tick carrying the pathogen. Other less common vectors of transmission to humans are through blood transfusions and childbirth, with the mother passing the infection to her child through the placenta (1).
While incidences of human Babesia infections are on the rise worldwide, the parasite remains difficult to detect through conventional blood screenings. Historically, Babesia infection is detected through a blood smear, a procedure that is both time-consuming and highly specialized (7). Because of the inherent challenges of diagnosing the infection, infected patients risk being misdiagnosed or experiencing treatment delays until their symptoms progress to potentially life-threatening severity or debilitating chronicity.
The protozoan can be found in ticks and their mammalian hosts throughout the world, from Europe to Asia to North America. Though the parasite occurs throughout the entire US, it is thought to be endemic in certain regions, including the northeast and New England, the Upper Midwest, and the West Coast (8, 9).
The Effects of Human Babesiosis
One of the most significant challenges in addressing Babesia infections in humans, in addition to the rapid increase in infections among human and other mammalian hosts, is the often immense variation in the course of the Babesiosis infection from one patient to another. Indeed, while many who have been infected with the parasite show few symptoms, if any, and are able to clear the pathogen without even knowing they’ve been infected, others can become gravely ill.
The principal risk of a Babesia infection in humans often rests in the individual’s ability to mount an effective immune response to the parasite. Thus, healthy adults with robust immune systems may never notice any physiological symptoms associated with the parasite. On the other hand, seniors, the immunocompromised, and individuals who have undergone splenectomies are at significant risk for developing severe Babesiosis and even of dying from the infection (1,10).
In vulnerable patients, the symptomology of Human Babesiosis is very much like the symptoms associated with malarial infection. In fact, the similarity is often so great that healthcare providers may be hard-pressed to accurately distinguish between the two (12). It’s not difficult to understand why: both originate from parasitic protozoans that inhabit and feed off of the red blood cells of the host.
In symptomatic cases of human Babesiosis, patients may experience fever, chills, fatigue, headache, muscle aches, cough, shortness of breath, respiratory distress, and an especially dangerous form of anemia called hemolytic anemia, in which the body’s red blood cells are destroyed faster than the bone marrow can replenish them. In extreme cases, the fever and blood loss associated with human Babesiosis are so significant that the patient cannot rally. This may result in organ failure and, possibly, death.
The Connection Between Babesia and Lyme Disease
Lyme Disease is one of the most prevalent and also among the least understood tick-borne diseases in the United States, affecting nearly 500,000 people, according to recent CDC estimates. However, studies suggest that there is often a strong correlation between Lyme Disease and Babesia.
Though Babesia and Lyme Disease are caused by different organisms, they are often transmitted through the same species of tick (13). Research is mounting that most ticks are host to multiple microbial infections simultaneously and that the bite of a single tick may introduce both the Lyme Disease and Babesia parasites (among others) into the human host. These non-Lyme organisms also transmitted by ticks are referred to as “coinfections” (14).
Current estimates suggest that as many as 1-in-5 Lyme Disease patients may also be infected with Babesia. That’s pretty alarming because there’s also strong evidence to show that the concurrence of Babesia and Borrelia-Burgdorferi, the microbe responsible for Lyme, can have synergistic effects, meaning that the severity of each disease is amplified by the presence of the other. Patients with Babesia and Lyme Disease often experience significantly more severe disease and worse outcomes than those experiencing a single infection (15, 16, 17).
Conventional Treatments for Human Babesiosis
As has been seen, patients who have been infected with the Babesia parasite can differ widely both in the trajectory and outcome of the infection. However, while many people who are infected with Babesia may require no treatment, those who are experiencing symptoms of acute Babesiosis infection, such as fever and chills, need prompt medical attention to arrest or slow the progression of the disease.
The standard course of treatment for human Babesiosis is a combination of antimicrobial (antibiotic) therapies. These are intended to kill the Babesia parasite. The most common drug combinations for Babesiosis include medications like atovaquone, azithromycin, hydroxychloroquine, or clindamycin (18).
Though these therapies have been shown to have some substantial efficacy in some patient populations, they are by no means either foolproof or harmless. Potential side effects of these antibiotics include allergic reactions, nausea, and vomiting (18).
Clindamycin and quinine appear to be particularly poorly tolerated by some patients and may lead not only to the adverse events described above but also to neurological impacts, including mild to moderate hearing loss and tinnitus (18). Frail and immunocompromised patients may not be able to tolerate these conventional regimens and may require supportive care and alternative therapies.
In addition to challenges in patients’ ability to tolerate conventional Babesiosis treatments, studies suggest that the long-term efficacy of these regimes is limited at best. Relapsing and persistent infection are common, especially for patients with significant immune deficiency (19, 20). The evidence suggests that not only are the Babesia protozoa strongly resistant to exposure to these therapies but that resistance capacities rapidly increase with each exposure, meaning that therapeutic efficacy can decrease significantly after the first few treatments (20, 21).
The Role of Integrative Medicine
As we’ve seen, though incidences of human Babesia infections are rapidly increasing around the world and particularly in the United States, conventional treatments have often been less than satisfactory for ensuring long-term recovery, particularly in vulnerable patients. However, evidence supporting the use of functional medicine in the prevention and treatment of Babesia and human Babesiosis is mounting.
Indeed, a number of botanical agents have been clinically demonstrated to improve immune function and reduce inflammation, and researchers have recently been able to empirically link these treatments to the treatment of human Babesia infection (9, 20). In fact, researchers have recently identified five herbal treatments that appear to exhibit a significant inhibitory effect on the Babesia duncani protozoan, the most common species of the Babesia parasite in the US (9, 20). These five herbs are Cryptolepis sanguinolenta, Artemisia annua (Sweet wormwood), Scutellaria baicalensis (Chinese skullcap), Alchornea cordifolia (African Chrismas bush), and Polygonum cuspidatum (Japanese knotweed) (9, 20).
Not only did the recent study affirm the promise of botanical medications in treating Babesia infections in humans, but it also found that three of the herbs, Cryptolepis sanguinolenta, Artemisia annua, and Scutellaria baicalensis, were as effective, and sometimes even more effective in killing and preventing the regrowth of the parasite than were the conventional therapeutics, clindamycin and quinine (9). While researchers caution that further research, including human clinical trials, is needed to determine the safety, efficacy, and recommended protocol for treating Babesia with botanical medicines, the study demonstrates promising, effective methods to treat Babesia, particularly for patients who are unable to tolerate conventional treatments or are experiencing persistent or relapsing infections.
Even as research into botanical therapeutics continues, there are already many integrative approaches to support patients experiencing Babesia infection. While patients with active Babesiosis will likely still require the standard treatment of antimicrobial and antibiotic agents, these can be used in conjunction with functional medicine approaches for enhancing the immune system, reducing inflammation, and promoting overall wellness.
As has been shown, immune dysfunction is by far the greatest risk factor both for the development of severe disease and for relapsing and persistent infection. Thus, one of the most important approaches to treating Babesia infections is to cultivate a lifestyle designed to support and even improve immune functioning. This would include getting consistent, quality sleep, eating a nutrient-rich diet of whole foods, protecting gut health through the use of prebiotics and probiotics, and supplementing with immune-boosting agents, such as Vitamin C, Vitamin B12, folate, Vitamin D, and antimicrobial peptides found in fermented foods.
In addition to boosting immune function, you’ll also want to prioritize inflammation reduction, as the inflammatory process is often the principal catalyst in the progression of Babesia disease, resulting in the worst of the damage done to the body’s cells and tissues. Probiotics including Lactobacillus plantarum, Lactobacillus brevis, and Lactobacillus collinoides, which are often found in fermented foods, can significantly reduce inflammation-producing cytokines. In addition to diet, supplementation, and lifestyle changes, inflammation may also be reduced through regenerative medicine approaches, including the use of platelet-rich plasma (PRP) infusions, and pulsed electromagnetic field therapy (PEMF).
If you think you or someone you love has contracted a tick-borne infection such as Babesia, or if you simply want to improve your health to provide protection if you are exposed to the pathogen, the multidisciplinary team at Temecula Center for Integrative Medicine can help you. We offer an array of integrative, functional, and regenerative medicine services to provide whole-person, individualized care to help you regain, or to maintain, health and wellness for decades to come. Contact us today to discuss how TCIM can serve you.
Jonathan Vellinga, MD is an Internal Medicine practitioner with a broad interest in medicine. He graduated Summa cum laude from Weber State University in Clinical Laboratory Sciences and completed his medical degree from the Medical College of Wisconsin.
Upon graduation from medical school, he completed his Internal Medicine residency at the University of Michigan. Dr. Vellinga is board-certified with the American Board of Internal Medicine and a member of the Institute for Functional Medicine.
info@tcimedicine.com
951-383-4333
Sources:
Curriero, F. C., Wychgram, C., Rebman, A. W., Corrigan, A. E., Kvit, A., Shields, T., & Aucott, J. N. (2021). The Lyme and Tickborne Disease Dashboard: A map-based resource to promote public health awareness and research collaboration. PloS one, 16(12), e0260122. https://doi.org/10.1371/journal.pone.0260122
Curriero, F. C., Wychgram, C., Rebman, A. W., Corrigan, A. E., Kvit, A., Shields, T., & Aucott, J. N. (2021). The Lyme and Tickborne Disease Dashboard: A map-based resource to promote public health awareness and research collaboration. PloS one, 16(12), e0260122. https://doi.org/10.1371/journal.pone.0260122
Jordan, R. A., & Egizi, A. (2019). The growing importance of lone star ticks in a Lyme disease endemic county: Passive tick surveillance in Monmouth County, NJ, 2006 - 2016. PloS one, 14(2), e0211778. https://doi.org/10.1371/journal.pone.0211778
Vannier, E. G., Diuk-Wasser, M. A., Ben Mamoun, C., & Krause, P. J. (2015). Babesiosis. Infectious disease clinics of North America, 29(2), 357–370. https://doi.org/10.1016/j.idc.2015.02.008
Antunes, S., Rosa, C., Couto, J., Ferrolho, J., & Domingos, A. (2017). Deciphering Babesia-Vector Interactions. Frontiers in cellular and infection microbiology, 7, 429. https://doi.org/10.3389/fcimb.2017.00429
Bajer, A., & Dwużnik-Szarek, D. (2021). The specificity of Babesia-tick vector interactions: recent advances and pitfalls in molecular and field studies. Parasites & vectors, 14(1), 507. https://doi.org/10.1186/s13071-021-05019-3
Nall, R. (2020, Feb. 14). What to know about Babesia. Medical News Today. https://www.medicalnewstoday.com/articles/babesia
Vannier, E., Gewurz, B. E., & Krause, P. J. (2008). Human babesiosis. Infectious disease clinics of North America, 22(3), 469–ix. https://doi.org/10.1016/j.idc.2008.03.010
Bay Area Lyme Foundation (2021). Five herbal medicines show potent activity against Babesia duncani in the lab. LymeDisease.org. https://www.lymedisease.org/five-herbal-medicines-babesia/
Chabria, S., & Ogbuagu, O. (2015). Fatal multiple deer tick-borne infections in an elderly patient with advanced liver disease. BMJ case reports, 2015, bcr2014208182. https://doi.org/10.1136/bcr-2014-208182
Yang, Y., Christie, J., Köster, L., Du, A., & Yao, C. (2021). Emerging Human Babesiosis with "Ground Zero" in North America. Microorganisms, 9(2), 440. https://doi.org/10.3390/microorganisms9020440
Knapp, K. L., & Rice, N. A. (2015). Human Coinfection with Borrelia burgdorferi and Babesia microti in the United States. Journal of parasitology research, 2015, 587131. https://doi.org/10.1155/2015/587131
Parveen, N., & Bhanot, P. (2019). Babesia microti-Borrelia Burgdorferi Coinfection. Pathogens (Basel, Switzerland), 8(3), 117. https://doi.org/10.3390/pathogens8030117
Djokic, V., Akoolo, L., Primus, S., Schlachter, S., Kelly, K., Bhanot, P., & Parveen, N. (2019). Protozoan Parasite Babesia microti Subverts Adaptive Immunity and Enhances Lyme Disease Severity. Frontiers in microbiology, 10, 1596. https://doi.org/10.3389/fmicb.2019.01596
Knapp, K. L., & Rice, N. A. (2015). Human Coinfection with Borrelia burgdorferi and Babesia microti in the United States. Journal of parasitology research, 2015, 587131. https://doi.org/10.1155/2015/587131
Diuk-Wasser, M. A., Vannier, E., & Krause, P. J. (2016). Coinfection by Ixodes Tick-Borne Pathogens: Ecological, Epidemiological, and Clinical Consequences. Trends in parasitology, 32(1), 30–42. https://doi.org/10.1016/j.pt.2015.09.008
Renard, I., & Ben Mamoun, C. (2021). Treatment of Human Babesiosis: Then and Now. Pathogens (Basel, Switzerland), 10(9), 1120. https://doi.org/10.3390/pathogens10091120
Bloch, E. M., Kumar, S., & Krause, P. J. (2019). Persistence of Babesia microti Infection in Humans. Pathogens (Basel, Switzerland), 8(3), 102. https://doi.org/10.3390/pathogens8030102
Zhang, Y., Alvarez-Manzo, H., Leone, J., Schweig, S., & Zhang, Y. (2021). Botanical Medicines Cryptolepis sanguinolenta, Artemisia annua, Scutellaria baicalensis, Polygonum cuspidatum, and Alchornea cordifolia Demonstrate Inhibitory Activity Against Babesia duncani. Frontiers in cellular and infection microbiology, 11, 624745. https://doi.org/10.3389/fcimb.2021.624745
Simon, M. S., Westblade, L. F., Dziedziech, A., Visone, J. E., Furman, R. R., Jenkins, S. G., Schuetz, A. N., & Kirkman, L. A. (2017). Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 65(7), 1222–1225. https://doi.org/10.1093/cid/cix477